These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 28185173)

  • 41. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study.
    Arecco L; Latocca MM; Blondeaux E; Riccardi F; Mocerino C; Guarneri V; Mioranza E; Bisagni G; Gasparini E; Puglisi F; Membrino A; Ferro A; Adamo V; Giovanardi F; Tamberi S; Donati S; Landucci E; Biganzoli L; Piccinini S; Pastorino S; de Azambuja E; Poggio F; Lambertini M; Del Mastro L
    Breast; 2024 Oct; 77():103769. PubMed ID: 39043079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
    Baek SY; Noh WC; Ahn SH; Kim HA; Ryu JM; Kim SI; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Jeong J; Park E; Kim SY; Lee MH; Kim LS; Lim W; Kim S; Kim HJ
    J Clin Oncol; 2023 Nov; 41(31):4864-4871. PubMed ID: 37607321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.
    Abbas W; Rao RR
    Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
    Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ
    J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.
    Lambertini M; Ceppi M; Poggio F; Peccatori FA; Azim HA; Ugolini D; Pronzato P; Loibl S; Moore HC; Partridge AH; Bruzzi P; Del Mastro L
    Ann Oncol; 2015 Dec; 26(12):2408-19. PubMed ID: 26347105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
    Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
    Expert Rev Anticancer Ther; 2016; 16(2):211-8. PubMed ID: 26634955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH
    Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
    Jiang M; Chen W; Hu Y; Chen C; Li H
    Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fertility after breast cancer treatment.
    Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
    Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.
    Lambertini M; Viglietti G; de Azambuja E
    Curr Opin Oncol; 2019 Jan; 31(1):43-51. PubMed ID: 30299291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.
    Barni S; Collovà E; Frassoldati A; Amoroso D
    Future Oncol; 2015; 11(8):1181-9. PubMed ID: 25832875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
    J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
    [No Abstract]   [Full Text] [Related]  

  • 55. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
    Kim HA; Lee JW; Nam SJ; Park BW; Im SA; Lee ES; Jung YS; Yoon JH; Kang SS; Lee SJ; Park KH; Jeong J; Cho SH; Kim SY; Kim LS; Moon BI; Lee MH; Kim TH; Park C; Jung SH; Gwak G; Kim J; Kang SH; Jin YW; Kim HJ; Han SH; Han W; Hur MH; Noh WC;
    J Clin Oncol; 2020 Feb; 38(5):434-443. PubMed ID: 31518174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study.
    Chen Y; Zhang R; Yan Y; Li H; Song G
    Breast Cancer Res Treat; 2024 Aug; 206(3):543-550. PubMed ID: 38709374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
    Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
    Perrone F; De Laurentiis M; De Placido S; Orditura M; Cinieri S; Riccardi F; Ribecco AS; Putzu C; Del Mastro L; Rossi E; Tinessa V; Mosconi AM; Nuzzo F; Di Rella F; Gravina A; Iodice G; Landi G; Pacilio C; Forestieri V; Lauria R; Fabbri A; Ibrahim T; De Maio E; Barni S; Gori S; Simeon V; Arenare L; Daniele G; Piccirillo MC; Normanno N; de Matteis A; Gallo C
    Eur J Cancer; 2019 Sep; 118():178-186. PubMed ID: 31164265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
    Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
    Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use.
    Fleege NMG; Li Y; Kidwell KM; Henry NL
    Clin Breast Cancer; 2023 Jun; 23(4):454-460. PubMed ID: 37076363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.